The compounds of Formula I are pro-drugs of CETP inhibitors having a central oxazolidinone ring. The compounds cyclize by the elimination of HX to form an oxazolidinone ring after administration to a patient.
The compounds of Formula I are pro-drugs of CETP inhibitors having a central oxazolidinone ring. The compounds cyclize by the elimination of HX to form an oxazolidinone ring after administration to a patient.
[EN] N-SUBSTITUTED INDOLE DERIVATIVES AND CONJUGATES FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS D'INDOLES N-SUBSTITUÉS ET CONJUGUÉS POUR LE TRAITEMENT DU CANCER
申请人:[en]DIACCURATE
公开号:WO2024003002A1
公开(公告)日:2024-01-04
The present invention relates to N-substituted derivatives of indoles of formula (I): and their use in the treatment of cancer. The invention further provides protein-drug conjugates, more particularly antibody-drug conjugates, from compounds of formula (I).
[EN] PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS<br/>[FR] PROMÉDICAMENTS D'INHIBITEURS DE CETP À BASE D'OXAZOLIDINONE
申请人:MERCK SHARP & DOHME
公开号:WO2010039474A1
公开(公告)日:2010-04-08
The compounds of Formula I are prodrugs of CETP inhibitors having a central oxazolidinone ring. The compounds cyclize by the elimination of HX to form an oxazolidinone ring after administration to a patient.